Harrow Announces New Appointments to its Board of Directors
January 29 2024 - 7:00AM
Business Wire
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical
company, today announced the appointments of Adrienne Graves,
Ph.D., and Lauren Silvernail to the Company’s Board of Directors,
effective immediately. Harrow’s Board now consists of six
members.
“I am delighted to announce the addition of Adrienne and Lauren
as new members to the Harrow Board of Directors,” said Mark L.
Baum, Chairman and Chief Executive Officer of Harrow. “Having
served in senior executive and Board positions at many leading
pharmaceutical companies, both Adrienne and Lauren are highly
respected business leaders who also share Harrow’s strategic vision
and strong commitment to grow into a leading U.S. ophthalmic
pharmaceutical company. The knowledge, expertise, and diverse
perspectives they bring to Harrow will be invaluable as we execute
our Strategic Plan and, ultimately, seek to maximize stockholder
value by leveraging our product portfolio, which is now one of the
most dynamic in the U.S. market. On behalf of the Harrow Board and
the entire Harrow Family, we wholeheartedly welcome Adrienne and
Lauren and look forward to working with them for many years to
come.”
About Adrienne Graves, Ph.D.
Dr. Adrienne Graves is a visual scientist by training and a
global industry leader in ophthalmology. Dr. Graves was Chief
Executive Officer of Santen Inc. from 2002 through 2010, following
seven years as Sr. V.P. of Worldwide Clinical Development. Previous
experience includes nine years at Alcon, where she built a Retinal
Electrophysiology Lab, directed clinical development, and served as
Director of International Ophthalmology. Dr. Graves was Chairman of
the Board at Iveric Bio until their 2023 acquisition by Astellas
and is currently on the Board of Directors at Qlaris Bio, Nicox,
Surface Ophthalmics, Opus Genetics, NVasc, JelliSee, and
Implandata. She previously held board positions at Encore Vision
(acquired by Novartis), Envisia (assets acquired by Aerie), TearLab
(now Trukera), Aerpio, and Akorn. In addition, Dr. Graves serves on
the Boards of the American Society of Cataract and Refractive
Surgeons (ASCRS), Glaucoma Research Foundation (GRF), American
Academy of Ophthalmology (AAO; Emeritus), Retina Global, Himalayan
Cataract Project, Foundation Fighting Blindness (FFB), and was a
founding Board member of OWL (Ophthalmic World Leaders). She is
Chairman of the RD (Retinal Degeneration) Fund, the venture arm of
FFB, and she co-founded Glaucoma 360. Her recent honors include the
Visionary Award (FFB), Catalyst Award (GRF), Visionary Award (OWL),
Bernice Brown Memorial Lecture Award (Women in Ophthalmology, or
WIO), and The Ophthalmologist 2021 and 2023 Power Lists. Dr. Graves
received an AB with Honors in Psychology from Brown University, a
Ph.D. in Psychobiology from the University of Michigan, and a
Postdoctoral Fellowship in Visual Neuroscience at the University of
Paris. She also mentors future leaders at Stanford University’s
Ophthalmic Innovation Program, demonstrating her commitment to
ophthalmic innovation and solving unmet needs in the treatment of
eye disease.
About Lauren Silvernail
Lauren Silvernail is a financial and strategic advisor to Boards
of Directors and corporate management teams. Over her career, she
has raised more than $1.3 billion in financing and completed
numerous transactions for emerging growth companies. From 2018 to
2022, Mrs. Silvernail served as Chief Financial Officer and
Executive Vice President of Corporate Development at Evolus, Inc.,
an aesthetic medicine company, where she led financing activities
and established infrastructure for the U.S. commercial launch of
the company’s first approved product. From 2013 to 2018, she was
Chief Financial Officer and Chief Business Officer at Revance
Therapeutics, Inc., a development stage aesthetic medicine company,
where she led the company’s initial public offering and subsequent
rounds of financing. From 2003 to 2012, Mrs. Silvernail was Chief
Financial Officer and Vice President Corporate Development at ISTA
Pharmaceuticals, a commercial ophthalmology company acquired by
Bausch and Lomb. Between 1995 and 2003, she served in operational
and corporate development roles for Allergan Inc., including Vice
President of Business Development. From 1990 to 1994, Mrs.
Silvernail was a general partner of Glenwood Ventures and a member
of the Boards of Directors of several Glenwood portfolio companies.
She began her career at Varian and Bio Rad Laboratories in product
marketing. Mrs. Silvernail holds an M.B.A. from the University of
California, Los Angeles with an emphasis in entrepreneurial finance
and accounting and a B.A. in Biophysics from the University of
California, Berkeley. She is currently a member of the Board of
Directors of Nicox S.A., an international ophthalmology company,
and Harpoon Therapeutics, Inc., a development stage oncology
company which recently announced it is being acquired by Merck.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical
company engaged in the discovery, development, and
commercialization of innovative ophthalmic pharmaceutical products
for the U.S. market. Harrow helps U.S. eyecare professionals
preserve the gift of sight by making its comprehensive portfolio of
prescription and non-prescription pharmaceutical products
accessible and affordable to millions of Americans each year. For
more information about Harrow, please visit harrow.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties which may
cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include, among others, risks related to: liquidity or
results of operations; our ability to successfully implement our
business plan, develop and commercialize our products, product
candidates and proprietary formulations in a timely manner or at
all, identify and acquire additional products, manage our pharmacy
operations, service our debt, obtain financing necessary to operate
our business, recruit and retain qualified personnel, manage any
growth we may experience and successfully realize the benefits of
our previous acquisitions and any other acquisitions and
collaborative arrangements we may pursue; competition from
pharmaceutical companies, outsourcing facilities and pharmacies;
general economic and business conditions, including inflation and
supply chain challenges; regulatory and legal risks and
uncertainties related to our pharmacy operations and the pharmacy
and pharmaceutical business in general; physician interest in and
market acceptance of our current and any future formulations and
compounding pharmacies generally. These and additional risks and
uncertainties are more fully described in Harrow’s filings with the
Securities and Exchange Commission, including its Annual Report on
Form 10-K and its Quarterly Reports on Form 10-Q. Such documents
may be read free of charge on the SEC's web site at sec.gov. Undue
reliance should not be placed on forward-looking statements, which
speak only as of the date they are made. Except as required by law,
Harrow undertakes no obligation to update any forward-looking
statements to reflect new information, events, or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240129007677/en/
Jamie Webb, Director of Communications and Investor Relations
jwebb@harrowinc.com 615-733-4737
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Jul 2024 to Aug 2024
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Aug 2023 to Aug 2024